Spojené štáty - angličtina - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 50 mg - carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings; gastrointestinal bleeding, ulceration, and perforation) . diclofenac sodium delayed-release tablets are indicated: - for relief of the signs and symptoms of osteoarthritis - for relief of the signs and symptoms of rheumatoid arthritis - for acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis diclofenac sodium delayed-release tablets are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see warnings; anaphylactic reactions, serious skin reactions) . - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients (see warnings; anaphylactic reactions, exacerbation of asthma related to aspirin sensitivity) . - in the setting of coronary artery bypass graft (cabg) surgery (see warnings; cardiovascular thrombotic events) .

Spojené štáty - angličtina - NLM (National Library of Medicine)

blenheim pharmacal, inc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 50 mg - carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets, usp and other treatment options before deciding to use diclofenac sodium delayed-release. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). diclofenac sodium delayed-release tablets are indicated: • for relief of the signs and symptoms of osteoarthritis • for relief of the signs and symptoms of rheumatoid arthritis • for acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis diclofenac sodium delayed-release tablets, usp are contraindicated in patients with known hypersensitivity to diclofenac. diclofenac sodium delayed-release should not be given to patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylac

Spojené štáty - angličtina - NLM (National Library of Medicine)

actavis pharma, inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 50 mg - carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings; gastrointestinal bleeding, ulceration, and perforation) . diclofenac sodium delayed-release tablets are indicated: - for relief of the signs and symptoms of osteoarthritis - for relief of the signs and symptoms of rheumatoid arthritis - for acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis diclofenac sodium delayed-release tablets are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see warnings; anaphylactic reactions, serious skin reactions) . - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other n

Spojené štáty - angličtina - NLM (National Library of Medicine)

nucare pharmaceuticals inc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 75 mg - carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets, usp and other treatment options before deciding to use diclofenac sodium delayed-release tablets, usp. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). diclofenac sodium delayed-release tablets are indicated: - for relief of the signs and symptoms of osteoarthritis - for relief of the signs and symptoms of rheumatoid arthritis - for acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis diclofenac sodium delayed-release tablets, usp are contraindicated in patients with known hypersensitivity to diclofenac. diclofenac sodium delayed-release should not be given to patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylactoid reactions, and precautions, preexisting asthma). diclofenac sodium delayed-release is contraindicated in the setting of coronary artery bypass graft (cabg) surgery (see warnings). external analgesic temporarily relieves minor aches and pains of muscles and joints due to: - simple backache - arthritis - strains - sprains

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - calcium alginate 80%; sodium alginate 20% - medicated dressing - active: calcium alginate 80% sodium alginate 20%

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - calcium alginate 80%; sodium alginate 20% - medicated dressing - active: calcium alginate 80% sodium alginate 20%

Malta - angličtina - Malta Medicines Authority

reckitt benckiser healthcare (uk) limited 103-105 bath road slough sl1 3uh, united kingdom - potassium hydrogen, carbonate, sodium alginate - oral suspension - potassium hydrogen carbonate 20 mg/ml sodium alginate 100 mg/ml - drugs for acid related disorders

Malta - angličtina - Malta Medicines Authority

reckitt benckiser healthcare (uk) limited 103-105 bath road slough sl1 3uh, united kingdom - potassium hydrogen, carbonate, sodium alginate - oral suspension - potassium hydrogen carbonate 20 mg/ml sodium alginate 100 mg/ml - drugs for acid related disorders

Malta - angličtina - Malta Medicines Authority

central procurement & supplies unit - sodium alginate - powder for oral suspension - sodium alginate 225 milligram(s) ; magnesium alginate 87.5 milligram(s) - drugs for acid related disorders

Malta - angličtina - Malta Medicines Authority

charles de giorgio limited - potassium hydrogen carbonate; sodium alginate - chewable tablet - potassium hydrogen carbonate 100 mg; sodium alginate 500 mg - drugs for acid related disorders